Keywords: KAI Pharma, Ono Pharma, KAI-4169, License for Japan, Hyperparathyroidism
KAI Pharma out-licenses KAI-4169 to Ono for Japan
Article | 19 September 2011
Privately-held USA-based drug discovery firm KAI Pharmaceuticals has signed an agreement with Ono Pharmaceutical (TYO: 4528) for the development and commercialization ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
